ALGS Q2 2023 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+86.5% YoY

Gross Profit

$7M100.0% margin

Operating Income

-$19M-278.0% margin

Net Income

-$19M-272.9% margin

EPS (Diluted)

$-0.43

QoQ Revenue Growth

+152.9%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$106M

Total Liabilities

$36M

Stockholders' Equity

$70M

Cash & Equivalents

$91M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$4M	+86.5%
Gross Profit	$7M	$4M	+86.5%
Operating Income	-$19M	-$20M	+6.1%
Net Income	-$19M	-$20M	+5.7%